Tukol Cough and Cold Honey Flavor

Description

Tukol-01 is a pharmaceutical compound identified for its therapeutic applications. The effective date for this drug is November 12, 2024. An image reference for tukol-01 is available, labeled as "tukol-01.jpg".

Uses and Indications

This drug is indicated for the relief of symptoms associated with colds, specifically nasal congestion and cough due to minor throat and bronchial irritation. It aids in loosening phlegm (mucus) and thinning bronchial secretions, facilitating drainage of the bronchial tubes.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The recommended dosage for adults and children aged 12 years and older is 2 teaspoons (10 mL) every 4 hours as needed. It is imperative that no more than 6 doses are taken within a 24-hour period to avoid potential overdose.

This product is not intended for use in children under 12 years of age. Healthcare professionals should advise caregivers to refrain from administering this medication to younger patients.

For accurate dosing, it is essential to use the dosing cup provided with the product. The dosing cup should be kept with the product to ensure proper measurement and administration.

Contraindications

There are no explicit contraindications identified for this product. However, it is essential to adhere to the recommended dosage guidelines, as exceeding the recommended dosage may pose risks to patient safety.

Warnings and Precautions

The use of this product is contraindicated in individuals currently taking prescription monoamine oxidase inhibitors (MAOIs), which are medications prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease. Additionally, it should not be used for a period of two weeks following the discontinuation of an MAOI. Healthcare professionals are advised to confirm with patients whether their prescription medications contain an MAOI prior to recommending this product.

Patients should be instructed to discontinue use and seek medical advice if they experience symptoms such as nervousness, dizziness, or insomnia. Furthermore, if symptoms do not improve within seven days or are accompanied by fever, or if a cough persists for more than seven days, recurs, or is associated with fever, rash, or a persistent headache, patients should be advised to contact their healthcare provider. These symptoms may indicate a more serious underlying condition that requires further evaluation.

In the event of an overdose, it is imperative to seek emergency medical assistance immediately or contact a Poison Control Center for guidance. Prompt action is essential to ensure patient safety and appropriate management of overdose situations.

Side Effects

Patients should be aware of the potential adverse reactions associated with this product. Serious adverse reactions may occur, particularly in individuals with specific pre-existing conditions. It is crucial to avoid using this product concurrently with prescription monoamine oxidase inhibitors (MAOIs) or within two weeks of discontinuing such medications, as this could lead to significant health risks.

Common adverse reactions that warrant immediate medical attention include symptoms such as nervousness, dizziness, or sleeplessness. Patients are advised to discontinue use and consult a healthcare professional if symptoms do not improve within seven days or if they are accompanied by fever. Additionally, if a cough persists for more than seven days, recurs, or is associated with fever, rash, or a persistent headache, these may indicate a serious underlying condition that requires medical evaluation.

Patients with a history of heart disease, high blood pressure, thyroid disease, diabetes, or urinary difficulties due to an enlarged prostate gland should seek medical advice before using this product. Furthermore, individuals experiencing a cough that produces excessive phlegm or those with chronic cough conditions, such as smoking-related issues, asthma, chronic bronchitis, or emphysema, should also consult a healthcare provider prior to use.

It is essential for patients to adhere to the recommended dosage, as exceeding this may lead to additional adverse reactions. For those taking other oral nasal decongestants or stimulants, consultation with a doctor or pharmacist is advised to avoid potential interactions.

Drug Interactions

The concomitant use of this medication with prescription monoamine oxidase inhibitors (MAOIs) is contraindicated. Patients should not use this medication while currently taking an MAOI or within 2 weeks of discontinuing an MAOI. MAOIs are typically prescribed for conditions such as depression, certain psychiatric disorders, or Parkinson's disease.

Additionally, it is advisable for patients to consult a healthcare professional, such as a doctor or pharmacist, prior to using this medication if they are concurrently taking any other oral nasal decongestants or stimulants. This precaution is essential to avoid potential adverse interactions and ensure safe use of the medication.

Packaging & NDC

Below are the non-prescription pack sizes of Tukol Cough and Cold Honey Flavor (dextromethorphan hydrobromide, guaifenesin, and phenylephrine hydrochloride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

This adult strength product is not intended for use in pediatric patients under 12 years of age. Children under 12 years should not use this medication.

Geriatric Use

Elderly patients may require special consideration when using this product. It is not intended for use in children under 12 years of age. For adults and children aged 12 years and older, the recommended dosage is 2 teaspoons (10 mL) every 4 hours, with a strict caution to not exceed the recommended dosage.

Before initiating treatment, it is advisable for elderly patients to consult a healthcare provider, particularly if they have pre-existing conditions such as heart disease, high blood pressure, thyroid disease, diabetes, or difficulties with urination due to an enlarged prostate gland. These conditions may necessitate careful monitoring and potential dose adjustments to ensure safety and efficacy in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no information available regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population.

Overdosage

Exceeding the recommended dosage of the medication can lead to serious health consequences. Healthcare professionals are advised to monitor patients closely for any signs of overdosage and to educate patients on the importance of adhering to prescribed dosages.

In the event of suspected overdosage, it is crucial to assess the patient for potential symptoms, which may vary depending on the specific medication involved. Common symptoms associated with overdosage may include, but are not limited to, gastrointestinal disturbances, neurological effects, and cardiovascular complications.

Management of overdosage should be initiated promptly. Healthcare providers should consider supportive care measures, which may include monitoring vital signs, providing symptomatic treatment, and, if necessary, implementing specific antidotes or interventions based on the medication's pharmacological profile.

In all cases of overdosage, it is recommended to contact a poison control center or seek specialized medical assistance to ensure appropriate management and care for the patient.

Nonclinical Toxicology

If pregnant or breastfeeding, it is advised to consult a health professional prior to use. No specific non-teratogenic effects have been identified. Additionally, there are no detailed findings related to nonclinical toxicology or animal pharmacology and toxicology available.

Postmarketing Experience

Postmarketing experience has identified the following adverse reactions reported voluntarily or through surveillance programs: dizziness, nervousness, and sleeplessness. These events have been documented in the context of routine pharmacovigilance activities.

Patient Counseling

Patients should be advised to keep this medication out of reach of children. In the event of an overdose, it is crucial to seek medical assistance or contact a Poison Control Center immediately.

Healthcare providers should instruct patients to discontinue use and consult a doctor if they experience symptoms such as nervousness, dizziness, or sleeplessness. Additionally, patients should be informed to seek medical advice if their symptoms do not improve within 7 days, or if they are accompanied by fever. A cough that persists for more than 7 days, recurs, or is associated with fever, rash, or a persistent headache may indicate a serious condition and warrants medical evaluation.

Patients should be encouraged to consult with their healthcare provider before using this medication if they have any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, difficulty urinating due to an enlarged prostate gland, a cough that produces excessive phlegm, or a chronic cough associated with smoking, asthma, chronic bronchitis, or emphysema.

It is also important for patients to ask their doctor or pharmacist before using this medication if they are currently taking any other oral nasal decongestants or stimulants. Patients must be reminded not to exceed the recommended dosage to avoid potential adverse effects.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a temperature range of 15-30°C (59-86°F). Refrigeration is not recommended, as it may compromise the integrity of the product. Proper handling and storage conditions must be adhered to in order to maintain product efficacy and safety.

Additional Clinical Information

The medication is administered orally. Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. It is also important to instruct patients to keep the medication out of reach of children and to seek medical assistance or contact a Poison Control Center immediately in the event of an overdose.

Drug Information (PDF)

This file contains official product information for Tukol Cough and Cold Honey Flavor, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)